A recent survey on "Singapore Investors' Financial Resilience" sponsored by Moomoo Financial Singapore Pte. Ltd. ("Moomoo Singapore") revealed that savvy investors (8.3%) used advanced financial technology as an essential part of their investment process.
Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
January 28, 2021
The DynamX Bioadaptor is a new class of treatment for Coronary Artery Disease.
SINGAPORE, January 28, 2021 /EINPresswire.com/ Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, recently presented at 30th Annual Live Interventions in Vascular Endotherapy conference organised by the National Heart Centre of Singapore (Singapore LIVE). The bioadaptor is the first coronary artery implant that adapts to vessel physiology.